GB2239243A - Glycerol derivatives - Google Patents
Glycerol derivatives Download PDFInfo
- Publication number
- GB2239243A GB2239243A GB9028015A GB9028015A GB2239243A GB 2239243 A GB2239243 A GB 2239243A GB 9028015 A GB9028015 A GB 9028015A GB 9028015 A GB9028015 A GB 9028015A GB 2239243 A GB2239243 A GB 2239243A
- Authority
- GB
- United Kingdom
- Prior art keywords
- propanol
- octadecylamino
- methyl
- derivative
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *N(*)CC(CO*)C=O Chemical compound *N(*)CC(CO*)C=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/20—Quaternary compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Abstract
Glycerol derivatives of the general formulae Ia, Ib and Ic <IMAGE> wherein R1 = H or C1-5 alkyl; R2 = C10-24 alkyl, R3 = aryl, C1-6 alkyl, alkylcarbamoyl, dialkylcarbamoyl; A = -P-O-(CH2)2-, -C-(CH2)N, -C-NH-(CH2)n-; n = 2-10; Y = Ammonium, alkylammonium, dialkylammonium, trialkylammonium, heterocycle, heterocycle with quaternary N heteratom; X<-> has no value if A has first of the above values, or otherwise is a pharmaceutically acceptable anion, have anti-tumour activity.
Description
TITLE:
Glycerol Derivatives
DESCRIPTION:
The invention relates to glycerol derivatives which are of interest for their antitumoral activity, to a method for their preparation and to pharmaceutical compositions containing them.
The invention provides glycerol derivatives of the general formula Ia, Ib and Ic
wherein:
R1 represents a hydrogen atom or an alkyl group
having from 1 to 5 carbon atoms;
R2 represents a straight chain or branched chain
alkyl group having from 10 to 24 carbon atoms;
R3 represents an aryl group, an alkyl group
having from 1 to 6 carbon atoms, an alkylcarbamoyl
group having from 2 to 7 carbon atoms or a
dialkylcarbamoyl group in which each alkyl group
has from 1 to 6 carbon atoms;
A represents a group of the formula
n being an integer of from 2 to 10;;
Y represents an ammonium group, an alkyl ammonium group having from 1 to 6 carbon atoms, a dialkylammonium or trialkylammonium group in which each
alkyl group independently has from 1 to 6 carbon
atoms, or a saturated or unsaturated heterocyclic
group containing a quaternary nitrogen hetero atom;
and
if A has the first of the values given above X has
no value but if A has the second or third of the
values given above X represents a pharmaceutically
acceptable anion.
The invention further provides pharmaceutically acceptable salts of the glycerol derivatives Ia, Ib and
Ic as above defined.
The invention also provides a process for the preparation of glycerol derivatives Ia, Ib and Ic as above defined, the process comprising reacting a propanol derivative of the general formula
wherein R 1R2 and R3 are as above defined and B2 represents a group of the formula -NR1'R2 or -N(SO2CH2)R2 wherein R1' represents an alkyl group having from 1 to 5 carbon atoms, R 2 is as above defined and (b represents a phenyl group with an oxo compound which has the formula
or O = C = N(CH2)nBr wherein n is as above defined; the said reaction being (a) carried out in the presence of an excess of a nitrogen compound which is ammonia, an alkylamine having from 1 to 6 carbon atoms, a dialkylamine or trialkylamine in which each alkyl group independently has from 1 to 6 carbon atoms or a saturated or unsaturated heterocyclic compound containing a nitrogen hetero atom, or (b) followed by reaction of the product with one of the nitrogen compounds listed in (a); and, if the product obtained by route (a) or route (b) contains a benzyl sulphonyl protected nitrogen atom, hydrogenolysing it to form a glycerol derivative I in which R1 represents a hydrogen atom.
The process according to the invention may be conducted in a single step, option (a) above, or as two steps, option (b) above. In either event, it is preferably carried out under a non-oxidising or inert atmosphere such as nitrogen; and desirably the propanol derivative is reacted with a 10 to 100% stoichiometric excess of the oxo compound.
When carried out as a two step process, the first step, that is the reaction of the propanol derivative II with the oxo derivative, is preferably carried out in an aprotic solvent in the presence of an organic base such as triethylamine. The most suitable temperature is from -10 C to ambient. The second step may then be carried out by heating the product of the first step with the nitrogen compound. Heating is preferably at 50 to 800C.
The product of the first step may simply be suspended or dissolved in the nitrogen compound and heated. When this is impracticable, e.g. because of the low boiling points of ammonia and the mono-, di- and tri-alkylamines of low molecular weight, a solvent may be used and the nitrogen compound is then preferably used in a 30 to 50% stoichiometric excess relative to the product of the first step.
When carried out as a one step process, the reaction is preferably conducted at 50 to 80"C. The nitrogen compound may, as in the second step of the two step process, be used to suspend or dissolve the propanol derivative II and the oxo derivative, either alone or in conjunction with an aprotic solvent.
It should be noted that if the desired glycerol derivative is of the general formula Ib or Ic and R1 represents a hydrogen atom, it is necessary to protect the secondary amino group with a benzylsulphonyl group. This can be removed at the end of the reation by hydrogenolysis.
Such protection is not necessary when preparing compounds of the general formula Ia, since the secondary amino group is then in a sterically hindered position.
Reaction scheme I below illustrates the process according to the invention as it relates to the preparation of the glycerol Ia; the corresponding reaction schemes for the preparation of the glycerol derivatives Ib and Ic are readily deduced by the skilled chemist and therefore need not be shown. In Reaction Scheme I, Z represents a nitrogen compound which is the parent to one of the quaternary nitrogen groups represented by Y.
Glycerol derivatives, and more particularly phosphocholine derivatives, have been described in EP 130527; one of these related compounds, effective in cancer treatment, 3-octadecylamino-l-tetradecyloxy-propan- -2-phosphocoline, and a reference compound, Et-18-OCH3 (methoxy-PAF;
Andreesen; 1988), have been retained for comparison purposes with the compounds of the invention. The results have shown that the compounds of the invention have a higher antitumoral activity, as evidenced in the pharmacological tests herewith.
Lastly, the invention provides a pharmaceutical composition comprising a glycerol derivative according to the invention or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable diluent or carrier.
The starting materials IIa, IIb and IIc may be prepared scoring to the reaction schemes II, III, IV and V below.
In particular:
The starting material II may be prepared according to reaction scheme II: the particularity of these reactions consists in the step 3a - 4a : the mechanism comprises 2 SN2 substitutions, with migration of the -OR3 and -NR1R2 groups, as described by K. Suzuki, K. Okano in
Synthesis 723 (Sept. 1983).
The starting material IIb may be prepared: - according reaction scheme III: the compound IIb may
comprise a protective group, when the final product Ib
is such that R1 stands for hydrogen. A deprotection
by hydrogenolysis will be conducted on the final
product; - according reaction scheme IV, route A or B,
specifically when R3 represents -CONH-alkyl or -CON
-dialkyl radical; the starting material 6b of reaction
scheme IV is identical with compound 2a of reaction
scheme II.
As regards the starting material IIc, reaction scheme V, please refer starting material IIb, first paragraph.
These steps are described below in the preparative examples.
REACTION SCHEME I
OR3 # NR1R2 OH IIA # Cl##+2 O=C=N(CH2)n Br+Z Br(CH2)n#Cl+Z OR3 OR2 OR3 # NR1R2 # NR1R2 # NR1R2 #(CH2)2Y O-#NH(CH2)nY O-#(CH2)nY Ia Ia Ia Reaction Scheme II
R1 R, oR1 rs Z r N - R2 NR2 O H-N - R2 > p C1Cj3 OH > OH OH A OH L OC la 2a R r N - R r OR3 ClMes OR, NaOR3 ;;R R OMes R NEt3 2 OCQ), OC 3a 4a OR3 H2/Pd \ " R, > r N Rz L OH IIa Reaction Scheme III
ros 1) HNa r os BH3 HO,C rio > R30"L THF o 2) Hal. R3 BH3 > lb 2b R1 R1 I I OH Mes C1 r OMes H-N - R2 N - R2 R30 > R30 yE OR3 OCH2 NEt3 OCH2 SOCH,8 3b 4b 5b R H2/Pd NR OR3 ,1 OH R1=R1 lIb R1H | so 02CH SO2CH2 R1=H SO,CH,I I I > OR3 > OR3 C1SO2CH2 OCH2 Me3SiI OH 5'b IIb Reaction Scheme IV
F N < Ra -OH 6b OC3 (A) I (B) R RN = C = 0 > N-C-C1 (R H) e ol (R, R' * H) NR1R2 -NRlRz OCNHR 7b -OCNRR' I a O 0 OC3 C H2/Pd V V NR1R2 -NRlRz OCNHR IIb -OCNRR' I a 0 0 OH OH Reaction Scheme V
O 9 1) 1 ) HNa 7\ BH3 2) > OR R, O H the 2 ) Ha 1. R3 THF OH OH Hal. R3 , OR3 lc 2c / R, OH OMes ,R1 LI - N - R2 Mes C1 H-N- R2 - OCH, NEt3 > OCH2 > OCH2 NEt, OR3 OR3 , OR3 3e 4c Sc S02CH2 SQCH2 I I N - R N - R2 ClSO2CH2 \ Cleavage OCH2 - OCH2 > OH OR3 OR3 Rl=H 5'e IIc R,=R,' IRI RL=Rl' I N - R2 > OH H2/Pd OR3 IIc I.Preparative example of the starting material Ila, according to the reaction scheme II: Rl=CH3, R2=C18H;, R3=CH3
Step 1: 3-(N-methyl-octadecylamino) -1, 2-propanediol (la)
A mixture of glycidol (4 ml, 60 mmol) and N-methyloctadecylamine (16 g, 60 mmol) in dry toluene (50 ml) was ref fluxed under stirring for 3 hours. After evaporation of the solvent, the residue was crystallized to yield 16 g (84%) of the title compound. m.p. 590C (Hexane).
M=357
TLC rf: 0.25 (CHCl3/MeOH, 80:20 v/v)
IR (cm 1) (nujol) 3300 (OH); 1090,1050 (C-O) tH-NMR: CDC13, 6 (TMS) 300 MHz 0.82 (t, 3H, CH3); 1.25 [5, 30H, (CH2)15]; 1.45 (t, 2H,
NCH2CH2); 2.3 (s, 3H, NCH3); 2.5 (m, 4H, CH2-N-CH2); 3.3 (large s., 1H, OH); 3.5 (m, 2H, H2COH); 3.75 (m, 1H, CHOH).
Step 2: 3-(N-methyl-octadecylamino)-1-trityloxy-propan-2-ol (2a) 50 mmol of la was treated for 12 hours with 60 mmol of trityl chloride and 120 mmol of triethylamine in 150 ml of boiling toluene. After conventional working up, the remaining oil was chromatographed (Flash chromatography, eluent chloroform) and gave 2a (yield 85%) m.p. 450C.
TLC rf: 0.44 (CHCl3/MeOH 95;5 v/v)
IR (cm-1) 3500 (OH); 3080, 3050, 3020 (ArCH); 1600 (C=C); 1080 (C-O) 1H-NMR: 300 MHz, CDCl3, 6 (TMS) 2.3 (s, 3H, NCH3); 2.5 (m, 4H, CH2-N-CH2); 3.2 (2m, 2H,
CH2Otrityl); 3.9 (m, 1H, H-COH); 7.3, 7.5 (m, 15H, trityl).
Step 3: 3- (N-methyl-octadecylamino) -2-methanesulphonyloxy-1-trityl- oxy-propane (3a) 18 g (30 mmol) of 2a was dissolved in 100 ml of dry diethyl ether and 50 ml of dichloromethane. 6.84 g (60 mmol) of methanesulphonyl chloride in 50 ml of dichloromethane was added under stirring, and the mixture was ref fluxed for 5 hours. Water was then added, and the organic phase was decanted, dried and evaporated. The crude product was chromatographed (eluent as in Step 2), yielding 16.7 g of 3a (80%).
M=677
TLC rf: 0.25 (CHCl3) IR (cm ) 1600 (C=C); 1370, 1180 (SO2); 1080 (C-O) 1H-NMR: 300 MHz CDC13 2.2 (s, 3H, NCH3); 2.4 (m, 2H, NCH2); 2.65 (m, 2H, CH2N); 3 (s, 3H, CH3SO2); 3.35 (m, 2H, CH2OTr); 4 (m, 1, CHOSO2).
Step 4: 3-methoxy-2-(N-methyl-octadecylamino)-1-trityloxy propane (4a)
This compound was prepared by reacting 3a with sodium methoxide. Yield 68%.
M=613
TLC rf: 0.42 (CHCl3/MeOH); 98:2 ; v/v)
IR (cm 1) 1120 (C-O-Me) 1050 (C-O) 1H-NMR: 300 MHz CDC13 6 (TMS) 2.2 (s, 3H, NCH3); 2.4 (m, 2H, NCH2); 3.05 (quintet, 1H,
CHN); 3.3 (s, 3H, OCH3); 3.35 (d, 2H, CH2OCH3); 3.6 (d, 2H, CH2OTr).
Step 5: 3-methoxy-2-(N-methyl-octadecylamino)-propanol (IIa)
This compound was obtained by hydrogenolysis for 5 hours at 400C at 40 psi (275880 pascals) of 4a in chloroform, using 10% palladium-on-charcoal as catalyst.
TLC rf: 0.17 (CHCl3/MeOH; 95:5; v/v) M=399.
IR (cm-1) 3410 (OH); 1120 (C-O-Me); 1050 (C-O-C) 'H-NMR: 300 MHz, C 2.25 (s, 3H, N-CH3); 2.5 (m, 2H, NCH2); 3 (m, 1H, CHN); 3.30 (m, 3H, CH2OCH3, OH); 3.35 (s, 3H, OCH3); 3.6 (m, 2H, CH2OH).
II. Preparative example of the starting material IIb
according reaction scheme III: R1=CH3, R2-C18H37, R3=CH3 Step 1: 2-phenyl-5-methoxy-1,3-dioxane (2b) 2-phenyl-5-hydroxy-1,3-dioxane 1b was obtained according to
Verkaade P.E. and Van Roon J.D. (Rec. Trav. Chim. Pays-Bas, 61, 831, 1942). m.p. 80 C.
10 g of the sodium salt of Ib, obtained by reaction with sodium hydride in dimethylformamide, was treated with 16 g of methyl iodide. The mixture was stirred at 50 C for 5 hours, and the dimethylformamide was eliminated in vacuo.
The residue was dissolved in dichloromethane, washed and dried. The solvent was evaporated off and the product was chromatographed on silica gel (eluent : dichloromethane) to give 2b.
Yield: 75% mp: 51 C; M=194
TLC rf: 0.32 (petroleum ether/diethyl ether 50:50)
IR (cm 1) 3100, 3060, 3040 (CH,), 1600 (C=C1), 1100 (C-O) 'H-NMR: 60 MMz, CDC13 TMS (C) 3.4(s, 3H, OCH3); 3.8 (s, 1H, HCOMe); 4 (m, 4H, CH2-O); 5.5 (s, 1H,
7.4 (m, 5H, ).
Step 2: 3-benzyloxy-2-methoxy-propanol (3b) 4.2 g of 2b was dissolved in 10 ml of tetrahydrofuran at OOC. A solution of BH3 in tetrahydrofuran (1M, 30 ml) was added slowly, under stirring. Stirring was continued for 48 hours at room temperature. The mixture was then cooled to OOC, quenched with cold water and extracted with diethyl ether. The solvent was eliminated and the crude product was chromatographed (eluent petroleum ether/diethyl ether, successively 80:20 and 70:30 by volume), yielding 2.6 g of 3b (62%).
TLC rf: 0.23 (petroleum ether/diethyl ether 50:50 v/v) viscous. M=196
IR (cm-1) 3400 (OH) 3100-3060-3040 (CH,) 1600 (C=C) 1100 (C-O) 'H-NMR: CDCl3, TMS. (6) 60 MHz 2.6 (1H, OH); 3.4 (s, 3H, OCH3); 3.5 (m, 5H, glycerol); 4.5 (s, 2H, CH2 #); 7.3 (5H, #).
Step 3: 3-benzyloxy-2-methoxy-1-methanesulphonyloxy-propane (4b)
To a solution of 5.88 g (30 mmol) of 3b and 10 ml of triethylamine in 100 ml of dry diethyl ether and 50 ml of dichloromethane, was added under stirring 6.84 g (60 mmol) of methanesulphonyl chloride in 50 ml of dichloromethane, and the mixture was ref fluxed for 5 hours. Water was then added, and the organic phase was decanted, dried and evaporated. The crude product was chromatographed (eluent petroleum ether/diethyl ether 80:20 by volume), to yield 6 g (74%) of 4b.
TLC rf: 0.35 (CHCl3) viscous. M=274
IR (cm-1) 1600 (C=C); 1350 (SO2); 1170 (SO2); 1100 (C-O-) 1H-NMR: CDC1Z, TMS (6) 60 MHz 3 (s, 3H, SO2CH3); 3.4 (s, 3H, OMe); 3.5 (d, 2H, CH2OCH2 #); 3.8 (m, 1H, HOOMe); 4.4 (m, 2H, CH2OSO2); 4.6 (s, 2H, CH2#); 7.4 (5H, ).
Step q; 3 -benzyloxy-2-methoxy-N-methyl-N-octadecyl -propylamine (5b) 5.4 g (20 mmol) of 4b was dissolved in 15 ml of dimethylsulphoxide and added to a solution of 5.7 g (20 mmol) of N-methyl-octadecylamine and 1.4 ml of triethylamine in 60 ml of dimethylsulphoxide. The mixture was stirred at 800C for 24 hours. The dimethylsulphoxide was eliminated. The residue was dissolved in dichloromethane, washed with water and dried. The crude product was chromatographed (eluent dichloromethane methanol 98:2 by volume), yielding 4.2 g of 5b (46%).
TLC rf: 0.42 (CH2Cl2/MeOH 95:5, v/v) viscous. M=461
IR (cm ) 1100 (C-O-) 1H-NMR: CDC13, TMS (6) 60MHz 0.9 (t, 3H, CH3); 1.25 (large sing, 32H); 2.3 (s, 3H,
NCH3); 2.6 (m, 4H, CH2-N-CHz); 3.45 (s, 3H, OCH3); 3.6 (m, 3H, CHOMe and CH2OCH2#); 4.6 (s, 2H, CH2; 7.4 (5H, ).
Steps: 3-(N-methyl-octadecylamino)-2-methoxy-propanol (IIb)
This compound was obtained by hydrogenolysis for 5 hours at 40 C at 40 psi(275880 pascals) of Sb in chloroform, using 10% palladium-on-charcoal as catalyst.
TLC rf: 0.35 (CH2Cl2/MeOH, 95:5, v/v). M=371
IR (cm ) 3450 (OH); 1110 (C-O-Me); 1060 (C-OH) H-NMR: 60MHZ, CDC13, 6 2.3 (s, 3H, NCH3); 2.6 (m, 4H, CH2NCH2); 3.45 (s, 3H, OCH3); 3.6 (m, 3H, CHOMe and CH2OH); 5.3 (1H, OH).
III. Preparative example of the starting material IIb
according reaction scheme III: R,=CH3, R2=C18H37, R3=C2H5
The procedure was the same as described in the preparative
example II, except that ethyl iodide was used in Step 1 in place of methyl iodide.
Step 1:
2-phenyl-5-ethoxy-l,3-dioxane (2b)
yield: 70%
TLC rf: 0.74 (CH2Cl2/MeOH, 98:2, v/v)
Step 2;
3-benzyloxy-2-ethoxy-propanol (3b)
yield: 78%
TLC rf: 0.47 (CH2Cl2/MeOH, 98:2, v/v)
Step 3:
3-benzyloxy-2-ethoxy-l-methanesulphonyloxy-propane (4b)
yield: 71%
TLC rf: 0.59 (CH2Cl2/MeOH, 99:1, v/v)
Step 4:
3-benzyloxy-2-ethoxy-N-methyl-N-octadecyl- propylamine (5b) yield: 61%
TLC rf: 0.44 (CH2Cl2/MeOH, 95:5, v/v)
Step 5: 3- (N-methyl-octadecylamino) -2-ethoxy-propanol (IIb) yield: 92%
TLC rf: 0.32 (CH2Cl2/MeOH, 95:5, v/v)
IV. Preparative example of the starting material IIb
according reaction scheme III: R1=H, R2=C,8H37, R3=CH3
The procedure of the steps 1 to 3 is the same as described
in the preparative example II, steps 1 to 3.
Step 4:
3-octadecylamino-2-methoxy-1-benzyloxy-propane (5b)
The procedure is the same as step .4, preparative example
II, using octadecylamine instead of N- methyl-octadecylamine.
TLC rf: 0.39 (CH2C12/MeOH, 95/5, v/v).
Step 5: Protection of the amino-group 3- ( N-benzylsulphonyl-octadecylamino ) -2-methoxy-l-benzyloxy- propane (5'b)
The compound 5'b was obtained by reaction of benzylsubhonyl chloride on 5b in the presence of NEt3 with CH2C12 as solvent, at room temperature for 24 hours.
IR (cm ) 1350 and 1190 (SO2)
Step 6.
3- ( N-benzylsulphonyl-octadecylamino ) -2-methoxy-propanol (IIb)
The benzyl group was cleaved using Me3SiI in CH2Cl2 at room temperature for 20 minutes.
TLC rf: 0.21 (hexane, ethylacetate 70:30 v/v).
V. Preparative example of the starting material IIb
according to reaction scheme N, route R,=CH3, R2=C18B37,
Step 1: 3- (N-methyl - octadecylamino) -2-methylcarbamoyloxy-l-trityloxy-propane (7b)
The preparation of 3- (N-methyl octadecylamino)- l-trityloxy
propan -2-01 6b is illustrated in the preparative example
I, step 2.
A solution of 3-(N-methyl- octadecylamino) -1-trityloxy -propane-2-ol 6b (6.10 M), pyridine (1 ml) and methyl
isocyanate (1.2 ml) in dry benzene (45 ml), was heated at
400C for three days. After elimination of the solvent, the
residue was purified by column chromatography with CH2Cl2
as eluent, to give 7b.
Yield: 80% M=661
TLC rf: 0.65 (CHCl3/MeOH, 98:2, v/v)
IR (cm ) 3350 (NH); 3080, 3050, 3020 (ArCH), 1695 (C=O);
1600 (C=C)
'H-NMR: 60 MHz, CDCl3, TMS, 6
2.8 (d, 3H, CONHCH3); 3.4 (m, 2H, CH2OTr); 4.8 (m, lH,
CONHCH3); 5 (m, 1H, HCOCON)
Step 2:
3- (N-methyl - octadecylamino) -2-methylcarbamoyloxy-propanol
(IIb)
This compound was obtained by hydrogenolysis of 7b.
TLC rf: 0.35 (CHCl3/MeOH, 90:10, v/v)
M=414
'H-NMR: 60 MHz, CDCl3, TMS, 6
1.8 (1H, OH); 3.8 (d, 2H, CH2OH); 5 (m, 1H, HCOCON); 6.4 (1H, CONHCH3)
VI. Preparative example of the starting material IIb
according to reaction scheme IV, route B: R1=CH3, R2=C18H37,
Step 1:
3-(N-methyl octadecylamino)-2-[N,N-(dimethyl)-carbamoyloxy] -1-trityloxy-propane (7b)
A solution of 3-(N-methyl-octadecylamino)- 1-trityloxypro- pan -2-ol 6b (5.4 mmol) and 1.4 g (13.5 mmol) of
dimethylcarbamoyl chloride in 30 ml of pyridine, was
ref fluxed for three days. After elimination of pyridine, the
residue was dissolved in dichloromethane, washed and dried.
The solvent was evaporated and the crude product
chromatographed on silica gel to yield 1.53 g (42%) of 7b.
M=675
TLC rf: 0.1 (CH2Cl2/MeOH, 91:1, v/v) -1
IR (cm ) 1700 (C=O); 1600 (C=C) 1H-NMR: 60 MHz, CDCl3, TMS, 6
2.3 (s, 3H, NCH3); 2.4 (m, 2H, NCH2); 2.6 (m, 2H, CH2N); 2.8 [5, 6H, CON(CH3)2]; 3.3 (m, 2H, CH2Otrityl); 7.3 (m, 15H,
trityl)
Step 2:
3-(N-methyl- octadecylamino)-2-[N,N-(dimethyl)-carbamoyloxy]
propanol (IIb)
The compound IIb was obtained by hydrogenolysis of 7b.
M=428
TLC rf: 0.43 (CH2Cl2/MeOH, 90:10, v/v)
IR (cm 1) 1700 (C=O)
1H-NMR: 60 MHz, CDCl3, TMS, 6
2.9 [s, 6H, N(CH3)2]; 3.8 (d, 2H, CH2OH); 4 (1H, OH); 4.9
(m, 1H, HCOCON)
VII. Preparative example of the starting compound IIc,
according to the reaction scheme V: R1=CH3, R2=C1,H37,
R3=CH3
Step 1: 2-phenyl-4-methoxymethyl-1,3-dioxolan (2c)
This compound was obtained by the same procedure as described in preparative example II, step 1 but starting from 2-phenyl-4-hydroxymethyl-l,3-dioxolan ic instead of 2-phenyl-5-hydroxy-1,3-dioxane lb. Yield 75%. Viscous product.
TLC rf: 0.60 (CH2Cl2/MeOH, 98:2 v/v) 1H-NMR: CDCl3, TMS, 60MHZ 6: 3.35 (s, 3H, OCH3); 3.6 (m, 2H, CH2OCH3); 3.9 (m, 3H,
CH2O, CHO); 5.8 (d, 1H,
7.4 (m, 5H, ).
Step 2: 3-methoxy-2-benzyloxy-propanol (3c)
This compound was obtained by the same procedure as described in preparative example II, step 2, but starting from 2-phenyl-4-methoxymethyl-1,3-dioxolan 2c instead of 2-phenyl-5-methoxy-1,3-dioxane 2b.
Yield: 71%
TLC rf: 0.23 (petroleum ether/diethylether, 50:50 v/v) 1H-NMR: CDC13, TMS, 60MHz, 6 2.5 (1H, OH); 3.3 (s, 3H, OCH3); 3.6 (m, 5H, glycerol backbone); 4.6 (s, 2H, H2 #); 7.3 (5H, #) ).
Step 3: 3-methoxy-2-benzyloxy-l-methanesulphonyloxy-propane (4c)
This compound was obtained by the same procedure as described in preparative example II, step 3, but starting from 3-methoxy-2-benzyloxy-propanol 3c instead of 3-benzyloxy-2-methoxy-propanol 3b.
Yield: 64%
TLC rf: 0.35 (CHCl3)
1H-NMR: CDC13, TMS, 60MHz, 6
3 (s, 3H, SO2CH3); 3.4 (s, 3H, OCH3); 3.5 (d, 2H, CH2OCH3);
3.8 (m, H, HC-OCH2#); 4.4 (m, 2H, CH2OSO2); 4.65 (s, 2H, CH2#); 7.3 (5H, #).
Step 4:
3-methoxy-2-benzyloxy-N-methyl-N-octadecyl-propylamine (5c)
This compound was obtained by the same procedure as
described in preparative example II, step4 , but starting
from 3-methoxy-2-benzyloxy-1-methanesulphonyloxy-propane 4c
instead of 3-benzyloxy-2-methoxy-1-methanesulphonyloxy- -propane 4b.
Yield: 50%
TLC rf: 0.42 (CH2Cl2/MeOH, 95:5, v/v)
'H-NMR: 60MHz, 6
0.9 (t, 3H, CH3); 1.3 (large s, 32H); 2.3 (s, 3H, NCH3);
2.5 (m, 4H, CH2NCH2); 3.4 (s, 3H, OCH3); 3.6 (m, 3H, CH2OMe, CHOCH2#); 4.7 (s, 2H, CH2; 7.3 (5H, ).
Step 5:
3-(n-methyl-octadecylamino)-1-mthoxy-propan-2-ol (IIc)
This compound was obtained by hydrogenolysis of Sc under
the conditions described in preparative example II, step 6.
Yield: 90%
TLC rf: 0.35 (CH2Cl2/MeOH, 95:5, v/v)
VIII. Preparative example of the starting compound IIc,
according to the reaction scheme V: R1=H, R2=C18H37, R3=CH3
The steps 1 to 3 are the same as described in preparative
example VII, steps 1 to 3.
Steps 4 to 6:
The procedure of preparation of 3-methoxy-2-benzyloxy-N- -octadecyl-propylamine (5c), of the protection reaction of
the amino group to obtain 3-methoxy-2-benzyloxy-N-(benzyl- suXhonyl-octadecyB-propylamine (5'c) and of the cleavage of
the benzyl group, was the same as described in preparative
example IV, steps 4 to 6.
The invention will be better understood from the
description of the following examples.
Example 1: 3 -methoxy-2- (N-methyl-octadecylamino) -propanol phosphocho
line
Compound of the formula Ia wherein Rl=CH3, R2=C18H37, R3=CH3,
Y=N (CH3)3 2 g (5 mmol) of 3-methoxy-2-(N-methyl-octadecylamino)propanol (IIa) and 3 ml of triethylamine were dissolved in
20 ml of dry benzene, and the mixture was cooled to 5 C
under nitrogen circulation. 1 g (7 mmol) of 2-chloro-2-oxo
1,3,2-dioxaphospholane in 4 ml of benzene was added under
stirring, and stirring was continued overnight. The amino
salt was filtered off and washed with benzene. The filtrate
was evaporated to dryness under reduced pressure. The
residue was dissolved in 20 ml of dry methyl cyanide and
transferred to a reactor. 20 ml of methyl cyanide,
saturated with gaseous trimethylamine was added, and the
mixture was heated at 650C for 24 hours. A solid separated
on cooling. It was filtered off and chromatographed on
silica gel (eluent chloroform : methanol 90:10, then 70:30 by volume, then methanol) to yield 1.1 g (39%) of the title compound.
M=564 m.p. 2440C.
TLC rf: 0.256 (CHCl3/MeOH/NH4OH; 70:30:7, v/v/v)
IR (cm ) 1240 (P=O); 1090 (C-O); 1040 (P-O-) 1H-NMR: 500 MHZ CD3OD (TMS) 6
0.8 (t, 3H, CH3); 1.25 [large s, 30H, (CH2)l5]; 1.45 (t, 2H,
NCH2CH2); 2.3 (s, 3H, NCH3); 2.45 (m, 2H, NCH2); 2.9 (m, 1H, CH2N); 3.3 (s, 3H, OCH3); 3.35 [s, 9H, N (CH3)3]; 3.5 (m,
2H, CH2OCH3); 3.7 (m, 2H, CH2N); 3.95 (m, 2H, CH2OP); 4.25
(m, 2H, POCH2).
Example 2:
3-methyoxy -2-(N-methyl-octadecylamino)-1-[6'-(N-pyridinium) -hexanoyloxty]-propane bromide
Compound of the formula Ia wherein R1=CH3, R2=C18H37, R3=CH3,
3-methoxy-2- (N-methyl-octadecylamino) -propanol (IIa) (3.5 g, 9 mmol) and Et3N (25 mmol) in 15 ml of ethanol free chloroform, were added dropwise to a solution of 5-bromohexanoyl chloride (10 mmol) in 10 ml of the same solvent, at 0 C under nitrogen circulation. The mixture was stirred for 15 hours at room temperature. After evaporation of solvent, 30 ml of dry pyridine was added to the obtained residue, and the mixture was then stirred at 800C under N2 for 24 hours.Pyridine was eliminated in vacuo and the residue was purified by column chromatography (eluent CHCl3 then CHCl3/MeOH 90:10) to yield 2.47 g (70%) of the title compound.
M=627
TLC rf 0.19 (CHCl3/MeOH, 70:30, v/v)
IR (cm 1) 1740 (C=O); 1640 (pyridine) H-NMR: 500 MHz, CDC13, TMS 6
1.4 (m, 2H, COCH2CH2CH2); 1.6 (m, 2H, COCH2CH2); 2.1 (m, 2H,
CH2CH2-N); 2.35 (t, 2H, COCH2); 5.05 (t, 2H, CH2N);
pyridinium 8.1 (t, 2H, H; 8.6 (d, 1H, H ) 9.5 (d, 2H, Hα) Example 3:
3-methoxy-2-(N-methyl-octadecylamino)-1-[5'-(N-pyridinium) -pentylcarbamoyloxy i-propane bromide
Compound of the formula Ia wherein F1=CH3, R2=C18H37, R3=CH3,
A mixture of 3-methoxy-2-(N-methyl-octadecylamino)-propanol
(IIa) (3.5 g, 9 mmol), 5-bromopentylisocyanate (12 mmol) and 30 ml of pyridine, was heated for two days at 800C under nitrogen circulation.Pyridine was eliminated in vacuo and the obtained residue was dissolved in CHCl3, washed and dried. The solvent was evaporated and the residue was chromatographed (eluent CHCl3 then CHCl3/MeOH, 95:5, 90:10) to yield 2.1 g (40%) of the title compound.
M=642
TLC rf: 0.23 (CHCl3/MeOH, 70:30, v/v)
IR (cm ) 3350 (NH), 1720, CONH), 1640 (pyridine) 'H-NMR: 500 MHz, CDCl3, TMS 6 1.4 (m, 2H, COCH2CH2CH2); 1.6 (m, 2H, COCH2CH2); 2.1 (m, 2H, CHz-CH2-N); 3.25 (t, 2H, CONHCH2); 5.05 (t, 2H, CH2N); 5.6 (NH); pyridinium 8.1 (t, 2H, Hss); 8.6 (d, 1H, H); 9.5 (d, 2H, Hα) Example 4: 3-(N-methyl-octadecylamino) -2-methoxy-propanol phosphocholine
Compound of the formula Ib wherein Rl=CH3, R2=Cl8H37, R3=CH3
Y=#(CH3)3 This compound was prepared by the same method as described
in example 1, but starting with 3-(N-methyl-octadecyl
amino)-2-methoxy-propanol(IIb), instead of 3-methoxy-2-(N -methyl-octadecylamino)-propanol (IIa).
Yield: 46% M=564
TLC rf: 0.22 (CHCl3/MeOH/NH4OH, 70:30 7,v/v/v)
IR (cm ) 1240 (P=O); 1100 (C-O-); 1040 (P-O).
'H-NMR: 500 MHz, CD3OD, TMS (6)
0.9 (t, 3H, CH3); 1.25 [large s, 30H, (CH2),s]; 1.5 (m, 2H,
NCH2CH2); 2.27 (s, 3H, NCH3); 2.4 (m, 2H, NCH2); 2:55 (m,
2H, CH2N); 3.2 [s, 9H, N (CH3)3)4 3.45 (s, 3H, OCH3); 3.55
(m, 1H, CHOCH3); 3.65 (t, 2H, CH2N); 3.9 (m, 2H, CH2OP); 4.3
(m, 2H, POCH2).
Example 5: 3- (N-methyl-octadecylamino) -2-ethoxy-propanol phosphocholine
Compound of the formula Ib wherein R,=CH3, R2=C,8H37, R3=C2H5,
Y=#(CH3)3 This compound was prepared by the same procedure as described in example 1, but starting with 3-(N-methyl-octadecylamino)-2-ethoxy-propanol IIb instead of 3-methoxy-2 -(N-methyl-octadecylamino) propanol IIa.
Yield: 32% MH+=579
TLC rf: 0.195 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v)
'H-NMR: 500 MHZ, CD3OD, TMS, 6 0.9 (2t, 6H, 2CH3); 1.25 [large s, 30H, (CH2)15); 1.5 (m, 2H, NCH2CH2); 2.27 (s, 3H, NCH3); 2.4 (m, 2H, NCH2); 2.55 (m, 2H, CH2N); 3.2 [s, 9H, N (CH3)3); 3.55 (m, 1H, CHOCH3); 3.65 (t+q, 4H, CH2N+OCH2); 3.9 (m,.2H, CH2OP); 4.3 (m, 2H, POCH2).
Example 6: 3-octadecylamino -2-methoxy-propanol phosphocholine
Compound of the formula Ib wherein R,=H, R2=C,8H37, R3=CH3,
Y=N(CH3)3 3- (N-benzylsulphonyl-octadecylamino ) -2-methoxy-propanol phosphocholine
This compound was obtained by the same procedure as described in example 1, but starting with 3-N,N-(benzylsulphonyl-octadecylamino-2-methoxy-propanol (IIb) instead of 3-methoxy-2-(N-methyl-octadecylamino)-propanol (IIa).
Yield: 35%
TLC rf: 0.29 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v) tHNMR: 500 MHZ, CD3OD, TMS (6) 3.15 [s+m, 12H, N(CH3)3 and
3.35 (s+m, 5H, OCH3 and CH2N-S02); 3.55 (m, 3H, CHOCH3 and
CH2N); 4.3 (m, 2H,
POCH2); 4.4 (m, 4H, CH2OP and SO2CH2#); 7.40 (5H, ).
3-octadecylamino-2-methoxy-propanol phosphocholine
Deprotection reaction:
This compound was obtained by hydrogenolysis of 3- (N-benzylsulphonyl-octadecylamino ) -2-methoxy-propanol phosphocholine, using Raney-Nickel as catalyst.
TLC rf: 0.17 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v)
M=550 H-NMR; 500 MHz, CD3OD, TMS (6) 3 (m, 2H, NCH2); 3.15 (m, 3H, NH and CH2N); 3.45 [s, 9H, + +
N(CH3)3]; 3.65 (s, 3H, OCH3); 3.8 (m, 3H, CHOCH3 and CH2N); 4.2 (m, 2H, POCH2); 4.4 (m, 2H, CH2OP).
Example 7: 3-(N-methyl-octadecylamino)-2-methylcarbamoyloXY-PrOPanol phosphocholine
Compound of the formula Ib wherein Rl=CH3, R2=C18H37,
Y=#(CH3)3 To a cooled (50C), stirred solution of 3-(N-methyl-octadecylamino)-2-methylcarbamoyloxy-propanol (IIb) (2.9 g, 7 mmol) and 3 ml of NEt3 in dry benzene (20 ml), was added 2-chloro-2-oxo -1,3,2-dioxaphospholane (2 g, 14 mmol) in benzene (4 ml) under nitrogen circulation. The mixture was stirred at room temperature for 8 hours, then filtered. The filtrate was evaporated off under reduced pressure. The residue was dissolved in dry CH3CN (50 ml) and transferred in a reactor. 30 ml of CH3CN saturated by gazeous NMe3 were added and the mixture was heated at 650C for 24 hours. The solvent was evaporated and the residue was chromatographed on silica gel (eluent CHCl3/MeOH, 90:10 then 70:30 and 30:70, then methanol) to yield 1.74 g (43%) of the title compound.
MH =581
TLC rf: 0.26 (CHCl3/MeOH/NH4OH, 70:30:7) IR (cm1) 3350 (NH); 1700 (C=O); 1250 (P=O); 1100, 1050 (C-O-C and P-O-C) 'H-NMR: CD3OD, 6 (TMS), 500 MHZ 2.3 (s, 3H, NCH3); 2.45 (m, 3H, NCH2); 2.6 (m, 2H, CH2N); 2.75 (d, 3H, CONHCH3); 3.4 [s, 9H, #(CH3)3]; 3.7 (m, 2H,
CH2N); 3.95 (m, 2H, CH2OP); 4.3 (m, 2H, POCH2); 5 (m, 1H,
HCOCON); 7 (1H, CONH)
Example 8:
3-(N-methyl- octadecylamino)-2-( N,N- dimethyl- carbamoyloxy) -propanol phosphocholine
Compound of the formula Ib wherein Rl=CH3, R2=C18H37,
Y=N(CH3)3 This compound was prepared by the same procedure as
described in example 7 but starting with 3-(N-methyl octa
decylamino) - 2-(N,N- dimethyl-carbamoyloxy) - propanol
instead of 3-(N-methyl octadecylamino)-2-methylcarbamoyloxy- -propanol.
Yield: 40% MH+=594
TLC rf: 0.3 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v)
IR (cm-1) 1700 (C=O); 1250 (P=O); 1100,1050 (C-O-C, P-O-C) 1H-NMR: CD3OD, TMS, 500 MHz, 6
2.2 (s, 3H, NCH3); 2.35 (m, 2H, NCH2); 2.55 (m, 2H, CH2N);
2.85 [d, 6H, CON(CH3)2]; 3.25 [s, 9H, N(CH3)3]; 3.55 (m, 2H,
CH2N); 3.9 (m, 2H, CH2OP); 4.25 (m, 2H, POCH2); 4.95 (m, 1H,
HCOCON)
Example 9:
3-(N-methyl-octadecylamino)-1-methoxy-propan-2-ol phospho
choline
Compound of the formula Ic wherein Rl=CH3, R2=C18H37, R3=CH3,
Y=#(CH3)3 This compound was obtained by the procedure described in example 1 but starting from 3-(N-methyl-octa decylamino)-1-methoxy-propan-2-ol (IIc) instead of 2-(N methyl-octadecylamino) -3-methoxy-propanol (IIa).
TLC rf: 0.24 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v)
Yield: 35% mp: 248 C
IR (cm 1) 1240 (P=O); 1100 (C-O); 1040 (P-O) 'H-NMR: 500MHz, CD3OD, (TMS)S 0.82 (t, 3H, CH3); 1.25 [s, 3OH, (CH2)15]; 1.45 (t, 2H, N-CH2CH2); 2.2 (s,3H,NCH3); 2.35 (m,2H,NCH2); 2.55 (m,2H,CH2N); 3.2 [s, 9H, #2(CH3)3]; 3.35 (s,3H,OCH3); 3.5 (m,2H,CH2OCH3); 3.6 (m, 2H, CH2N+); 4.25 (m, 2H, POCH2); 4.3 (1H,CHOP).
Example 10: 1-octadecylamino-3-methoxy-propan-2-ol phosphocholine
Compound of the formula Ic wherein R1=H, R2=C18H37, R3=CH3,
Y#(CH3)3 This compound was obtained by the procedure as described in
example 6, comprising the preparation and the deprotection
of -1-(N-(benzylsulphonyl-octadecylamino)-3-methoxy- propan -2-01 phosphocholine.
M=550
TLC rf: 0.20 (CHCl3/MeOH/NH4OH, 70:30:7, v/v/v)
'H-NMR; 500 MHz, OD3OD, (TMS) 6
2.9 (m, 3H, NH and NCH2); 3.1 (m, 2H, CH2N); 3.4 [s, 9H, #(CH3)3]; 3.55 (s, 3H, OCH3); 3.7 (m, 2H, CH2#); 3.85 (m,
2H, CH2OMe); 4.5 (m, 2H, POCH2); 4.6 (m, 1H, CHOP).
TOXICITY
The toxicity of the compounds of the invention, has been determined per os on mice, by usual methods. Their LD50 values are higher than 650 mg/kg.
PHARMACOLOGY
The compounds of the invention have been examined for their ability to inhibit in vitro tumor cell proliferation.
They inhibit HL60 and A.427 tumor cell proliferation after 24 hours.
HL60: promyelocytic leukemia cell line
A.427: lung carcinoma cell line
They show a cytostatic effect at the dose of 0.02 mM which is not a toxic dose for the two human tumor cell lines.
Overall, the lung carcinoma cell line resulted more sensitive than the promyelocytic leukemia cell line.
The effect of the compounds of the invention on long-term proliferation, has been more precisely described above.
All of the examples of the invention have been tested and compared with two related compounds of the prior art: - the 1-0-octadecyl- 2-0-methylglycero- 3-phosphocholine
(Et-18-OCH3 or methoxy PAF ; Andreesen, 1988), - the 3-octadecyl-l-O-tetradecyl-propan-l, 2-diol-2-0-phos- phocholine [compound (D)].
For this study, a colon adenocarcinoma cell line, called
HT.29, have been used; they are anchorage-dependent cells.
The HT.29 cells were grown in Mc Coy medium (Flow Labs), supplemented with 10% foetal bovine serum (FBS; Gibco). The growth media contain 100 U/ml of penicillin and 100 Mg/ml of streptomycin (Flow Labs).
The compounds of the invention and the compounds (D) and Et-18-OCH3, were dissolved in a solution containing 60% ethanol and 40% phosphate buffer saline (PBS; Flow Labs).
Serial dilutions were prepared in PBS. The dose tested was 0.02 mM. The treatment time lasted 24 hours at 370C.
The effect of the compounds of the invention on long-term cell proliferation and survival, has been evaluated by studying the plating efficiency and colony morphology of
HT.29. To carry out this study, 5.102 HT.29 cells, previously treated with the different compounds of the invention for 24 hours, were seeded into 25 cm2 growth area tissue culture flasks.
These cell cultures were then incubated at 370C for 15 days. At the end of this incubation time, the cell cultures were rinsed twice with PBS, fixed with 70% ethanol for 30 minutes and stained for the same length of time with 10 Giemsa (Sigma Chemicals).
The results are expressed as 'relative plating efficiency (P.E.)' values calculated as follows:
P.E. = Number of colonies formed x 100
Number of cells plated and summarized in the following tables.
It has been found that the colonies formed after treatment of compounds of the invention, have lost their regular profile, have a lower reactivity to the Giemsa stain and, overall their size is smaller than that of the untreated colonies.
COMPOUNDS P.E. (%) Control 100#4.3 #(-18-OCH3 39#1.5 (D) 34#2.3## EX 1 21.9 + 1.0 *** EX2 24.3+1.4** EX 3 27.1 + 2.1 * EX4 45.6+3.ONS
COMPOUNDS P.E. (%) EX5 20.6 + 1.7 ** EX6 26.4#1.7## EX 7 22.3 + ****** EX8 19.9#0.9### EX9 20.2+ 1.2** EX 10 25.4 + 2.7 * The statistical symbols refer to the comparison between each compound with the reference Et-18-OCH3. The different symbols: NS, *, ** and *** mean that the result is respectively not significative, significative, very significative and highly significative.
POSOLOGY
In human therapy, the compounds of the invention are preferably administered by the IV route. Usual posology is from 2.5 to 5 mg/dm2 of the tumour under treatment per diem, three to six days per month in slow perfusion.
Claims (24)
1. A glycerol derivative of the general formula Ia, Ib or Ic
wherein:
R1 represents a hydrogen atom or an alkyl group
having from 1 to 5 carbon atoms;
R2 represents a straight chain or branched chain
alkyl group having from 10 to 24 carbon atoms;
R3 represents an aryl group, an alkyl group
having from 1 to 6 carbon atoms, an alkylcarbamoyl
group having from 2 to 7 carbon atoms or a
dialkylcarbamoyl group in which each alkyl group
has from 1 to 6 carbon atoms;
A represents a group of the formula
n being an integer of from 2 to 10;
Y represents an ammonium group, an alkyl ammonium group having from 1 to 6 carbon atoms, a dialkylammonium or trialkylammonium group in which each alkyl group independently has from 1 to 6 carbon atoms, or a saturated or unsaturated heterocyclic group containing a quaternary nitrogen hetero atom; and if A has the first of the values given above X has no value but if A has the second or third of the values given above X represents a
pharmaceutically acceptable anion; or a pharmaceutically acceptable salt of such a derivative.
2. 3-Methoxy-2-(N-methyl-octadecylamino)-propanol phosphocholine.
3. 3-Methoxy-2-(N-methyl-octadecylamino)-1-[6'-(N -pyridinium)-hexanoyloxy]-propane bromide.
4. 3-Methoxy-2-(N-methyl-octadecylamino)-1-[5'-(N -pyridinium)-pentylcarbamoyloxy]-propane bromide.
5. 3-(N-Methyl-octadecylamino)-2-methoxy-propanol phosphocholine.
6. 3-(N-Methyl-octadecylamino)-2-ethoxy-propanol phosphocholine.
7. 3-Octadecylamino-2-methoxy-propanol phosphocholine.
8. 3- (N-Methyl-octadecylamino ) -2-methylcarbamoyloxy- -propanol phosphocholine.
9. 3- (N-Methyl-octadecylamino) -2- (N, N-dimethyl- -carbamoyloxy)-propanol phosphocholine.
10. 3-(N-Methyl-octadecylamino)-l-methoxy-propan-2-ol phosphocholine.
11. l-Octadecylamino-3-methoxy-propan-2-ol phosphocholine.
12. A process for the preparation of a glycerol derivative according to claim 1, the process comprising reacting a propanol derivative of the general formula
wherein R1, R2 and R3 are as defined in claim 1 and B2 represents a group of the formula -NR1 1R2 or -N(SO2CH2)R2 wherein R1' represents an alkyl group having from 1 to 5 carbon atoms, R2 is as defined in claim 1 and represents a phenyl group with an oxo compound which has the formula
or O = C = N(CH2)n Br wherein n is as defined in claim 1; the said reaction being (a) carried out in the presence of an excess of a nitrogen compound which is ammonia, an alkylamine having from 1 to 6 carbon atoms, a dialkylamine or trialkylamine in which each alkyl group independently has from 1 to 6 carbon atoms or a saturated or unsaturated heterocyclic compound containing a nitrogen hetero atom, or (b) followed by reaction of the product with one of the nitrogen compounds listed in (a); and, if the product obtained by route (a) or route (b) contains a benzylsulphonyl protected nitrogen atom, hydrogenolysing it to form a glycerol derivative I in which R1 represents a hydrogen atom.
13. A process according to claim 12, option (a), in which the solvent for the reaction between the propanol derivative and the oxo derivative is the nitrogen compound or a mixture thereof with an aprotic solvent.
14. A process according to claim 12, option (a), or claim 13 in which the reaction is carried out at a temperature of from 50 to 80"C.
15. A process according to claim 12, option (b), in which the reaction between the propanol derivative and the oxo derivative is carried out in an aprotic solvent.
16. A process according to claim 12, option (b), or claim 15 in which the reaction between the propanol derivative and the oxo derivative is carried out at a temperature of from -10 C to ambient temperature.
17. A process according to claim 12, option (b) or claim 15 or claim 16 in which the reaction between the propanol derivative and the oxo derivative is carried out in the presence of an organic base.
18. A process according to claim 17 in which the organic base is triethylamine.
19. A process according to claim 12, option (b) or any of claims 15 to 18 in which the reaction of the product of the first step with the nitrogen compound is carried out at a tempature of from 50 to 80"C.
20. A process according to claim 12, option (b), or any of claims 15 to 19 in which the product of the first step is reacted with a 30 to 50% stoichiometric excess of the nitrogen compound.
21. A process according to claim 12, option (b), or any of claims 15 to 19 in which the reaction of the product of the first step with the nitrogen compound is effected by heating the said product in solution in the nitrogen compound.
22. A process according to any of claims 12 to 21 in which the propanol derivative is reacted with a 10 to 100% stoichiometric excess of the oxo compound.
23. A process according to any of claims 12 to 22, which process is carried out under a non-oxidising or insert atmosphere.
24. A pharmaceutical composition comprising a glycerol derivative according to any of claims 1 to 11 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable diluent or carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9028015A GB2239243B (en) | 1989-12-22 | 1990-12-24 | Glycerol derivatives |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898929075A GB8929075D0 (en) | 1989-12-22 | 1989-12-22 | Glycerol derivatives |
| GB898929074A GB8929074D0 (en) | 1989-12-22 | 1989-12-22 | Glycerol derivatives |
| GB9028015A GB2239243B (en) | 1989-12-22 | 1990-12-24 | Glycerol derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9028015D0 GB9028015D0 (en) | 1991-02-13 |
| GB2239243A true GB2239243A (en) | 1991-06-26 |
| GB2239243B GB2239243B (en) | 1993-05-12 |
Family
ID=27264865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9028015A Expired - Fee Related GB2239243B (en) | 1989-12-22 | 1990-12-24 | Glycerol derivatives |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2239243B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| US7129227B1 (en) | 1994-08-29 | 2006-10-31 | Wake Forest University | Lipid analogs for treating viral infections |
| US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| US7551837B2 (en) | 2001-08-31 | 2009-06-23 | Thomson Licensing | Sequence counter for an audio visual stream |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0130527A1 (en) * | 1983-07-02 | 1985-01-09 | A. Nattermann & Cie. GmbH | 1-0-Alkyl-3-amino-propan-1.2-diol-2-0-phospholipids, process for producing the same and pharmaceutical preparations containing the same |
| EP0157609A2 (en) * | 1984-04-03 | 1985-10-09 | Takeda Chemical Industries, Ltd. | Lipid derivatives their production and use |
| WO1986002349A1 (en) * | 1984-10-11 | 1986-04-24 | Takeda Chemical Industries, Ltd. | Lipid derivatives |
-
1990
- 1990-12-24 GB GB9028015A patent/GB2239243B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0130527A1 (en) * | 1983-07-02 | 1985-01-09 | A. Nattermann & Cie. GmbH | 1-0-Alkyl-3-amino-propan-1.2-diol-2-0-phospholipids, process for producing the same and pharmaceutical preparations containing the same |
| EP0157609A2 (en) * | 1984-04-03 | 1985-10-09 | Takeda Chemical Industries, Ltd. | Lipid derivatives their production and use |
| WO1986002349A1 (en) * | 1984-10-11 | 1986-04-24 | Takeda Chemical Industries, Ltd. | Lipid derivatives |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129227B1 (en) | 1994-08-29 | 2006-10-31 | Wake Forest University | Lipid analogs for treating viral infections |
| US7141557B2 (en) | 1994-08-29 | 2006-11-28 | Wake Forest University | Lipid analogs for treating viral infections |
| US7294621B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for combating tumors |
| US7294620B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for inhibiting HIV-1 activity |
| US7294619B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for inhibiting the activity of hepatitis B antigen |
| US8106032B2 (en) | 1994-08-29 | 2012-01-31 | Wake Forest University | Lipid analogs for combating tumors |
| US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US8138200B2 (en) | 1999-10-28 | 2012-03-20 | Wake Forest University | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| US7551837B2 (en) | 2001-08-31 | 2009-06-23 | Thomson Licensing | Sequence counter for an audio visual stream |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2239243B (en) | 1993-05-12 |
| GB9028015D0 (en) | 1991-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5187186A (en) | Pyrroloindole derivatives | |
| AU617304B2 (en) | Novel cc-1065 analogs | |
| CA2032254C (en) | Glycerol derivatives, a preparation process of the same and therapeutical compositions containing them | |
| CA2611721A1 (en) | Compounds for preparing immunological adjuvant | |
| GB2239243A (en) | Glycerol derivatives | |
| Bhatia et al. | Stereospecific synthesis of ether and thioether phospholipids. The use of L-glyceric acid as a chiral phospholipid precursor | |
| AU630056B2 (en) | 3-(n-methyl-n-alkyl)-amino 2-methoxymethylene propan 1-ol derivatives, a preparation process of the same and therapeutical compositions containing them | |
| EP0013818A1 (en) | Organosilicon compounds, their preparation and anti-tumor agents containing the same | |
| EP0130527B1 (en) | 1-0-alkyl-3-amino-propan-1.2-diol-2-0-phospholipids, process for producing the same and pharmaceutical preparations containing the same | |
| GB2403949A (en) | Combretastatin derivatives | |
| US4565659A (en) | Substituted aminoalkanol phospholipids | |
| DK151630B (en) | ANALOGY PROCEDURE FOR PREPARING N-PHTHALIDYL-5-FLUORURACYL DERIVATIVES | |
| Argüello-Velasco et al. | Month 2019 A Straightforward Synthesis of Six-Membered-Ring Heterocyclic α-Aminophosphonic Acids from N-Acyliminium Ions | |
| Tietze et al. | Highly Selective Allylation of Alkyl Methyl Ketones in the Presence of Chiral 2‐Amino Alcohol Derivatives | |
| Derr et al. | On the Search of a Silver Bullet for the Preparation of Bioinspired Molecular Electrets with Propensity to Transfer Holes at High Potentials (Supplementary Materials) | |
| JPH0318611B2 (en) | ||
| JPS60197654A (en) | Anticancer (alkylsulfonyl)methanesulfonic acid ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19981224 |